This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Michael Drummond | |
|---|---|
| Name | Michael Drummond |
| Birth date | 1950s |
| Birth place | Glasgow, Scotland |
| Nationality | British |
| Alma mater | University of Edinburgh; London School of Economics |
| Occupation | Health economist; academic; author |
| Known for | Health technology assessment; cost-effectiveness analysis; health policy |
Michael Drummond
Michael Drummond is a British health economist and academic known for his work in health technology assessment, cost-effectiveness analysis, and health policy. He has held academic posts at leading institutions and advised national and international agencies on the economic evaluation of health interventions. Drummond's scholarship has influenced methodological standards used by bodies such as national health services and regulatory agencies.
Drummond was born in Glasgow and educated in Scotland before undertaking higher studies in economics and public policy. He completed undergraduate studies at the University of Edinburgh and postgraduate training at the London School of Economics and the University of York, where he developed expertise in health economics under the mentorship of scholars associated with Nuffield College, Oxford and the Royal Society of Edinburgh. His early training intersected with contemporary debates in the National Health Service and comparative work involving the World Health Organization and the European Commission on health financing.
Drummond's academic career includes appointments at the University of York, the University of Sheffield, and visiting positions at institutions such as Harvard University, Columbia University, and the University of Toronto. He has served on advisory committees for agencies including the National Institute for Health and Care Excellence, the European Medicines Agency, and the World Health Organization. His consultancy work has linked him to healthcare authorities in the United Kingdom, United States, Canada, Australia, and countries within the European Union. Drummond has collaborated with multidisciplinary teams at think tanks and research centers such as the Nuffield Trust, the King's Fund, and the Health Foundation.
Drummond's research centers on methods for economic evaluation in health care, particularly cost-effectiveness analysis, cost-utility analysis, and health technology assessment. He contributed to methodological frameworks adopted by the National Institute for Health and Care Excellence, the European Commission's health technology assessment initiatives, and guidance used by the Organisation for Economic Co-operation and Development. His work addresses the valuation of quality-adjusted life years, the incorporation of patient preferences measured by instruments such as the EQ-5D, and modeling techniques used in pharmacoeconomic assessments submitted to regulatory bodies like the European Medicines Agency and the Food and Drug Administration.
Drummond has examined the intersection of pricing and reimbursement policy with market access strategies pursued by pharmaceutical firms and device manufacturers, engaging with stakeholders including the Association of the British Pharmaceutical Industry and multinational firms headquartered near clusters such as Cambridge and Boston, Massachusetts. He has also investigated priority-setting and resource allocation in health systems comparable to the NHS Scotland, the Canadian Institute for Health Information, and the Australian Government Department of Health. His contributions include methodological advances in decision-analytic modeling, probabilistic sensitivity analysis, and the presentation of cost-effectiveness results to policy audiences at venues such as the World Health Assembly and the European Health Forum Gastein.
Drummond is co-author or editor of widely cited texts and reports used in academic courses and guideline development, including textbooks adopted at the London School of Economics and the University of York. His publications appear in leading journals such as Health Economics (journal), The BMJ, The Lancet, and Pharmacoeconomics. He has authored chapters in handbooks published by organizations including the World Health Organization and the Organisation for Economic Co-operation and Development. Drummond's bibliographic corpus spans systematic reviews of health economic methods, methodological papers on trial-based economic evaluations, and applied evaluations informing reimbursement decisions at agencies like the National Institute for Health and Care Excellence and the Scottish Medicines Consortium.
Drummond's contributions have been recognized by professional societies and governmental bodies. He has received fellowships and honorary appointments from institutions such as the Royal Society of Edinburgh and has been invited to deliver named lectures at venues including the Royal College of Physicians and the Faculty of Public Health (UK). His work has informed policy awards and institutional commendations linked to improvements in health technology assessment across the European Union and in Commonwealth countries. He has been cited in policy documents produced by the World Health Organization and the Organisation for Economic Co-operation and Development.
Drummond has combined academic responsibilities with advisory roles in public policy and industry forums, maintaining residences in the United Kingdom and undertaking frequent travel to academic conferences in locations such as Geneva, Brussels, and Washington, D.C.. He has mentored doctoral students who have taken positions at universities including the University of York, the London School of Economics, and McGill University. Outside academia, he has participated in charitable initiatives linked to health services and global health projects coordinated by organizations such as Médecins Sans Frontières and national health charities.
Category:British health economists Category:Living people